Comparative Pharmacology
Head-to-head clinical analysis: RENO 60 versus RENOGRAFIN 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENO 60 versus RENOGRAFIN 76.
RENO-60 vs RENOGRAFIN-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RENO-60 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolality iodinated contrast agent. It attenuates X-rays by blocking photons due to the high atomic number of iodine, thereby enhancing vascular and tissue contrast. It distributes in extracellular fluid and is excreted unchanged by glomerular filtration.
Radiopaque contrast agent that attenuates X-rays by absorbing them due to its high iodine content, allowing visualization of vascular structures and organs during radiographic procedures.
Intravenous administration of 0.5-1.0 mL/kg (up to 150 mL total) per radiographic procedure. Dose may be repeated once if needed.
Intravenous administration of 50-100 mL (14.1-28.2 g iodine) as a single dose for angiography; dose varies by procedure and patient size.
None Documented
None Documented
Terminal elimination half-life approximately 30-60 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Terminal elimination half-life: 1–2 hours (normal renal function); prolonged to >20 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal excretion via glomerular filtration; up to 20% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<5%)
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent